SCHEMBL367927

SCHEMBL367927

CN(C)c1cc(N2CCNCC2=O)c2nc(C(=O)NCc3ccc(F)cc3)c(O)c(=O)n2c1

nearest known ligand 0.43

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
CYP2C9 P11712 2/20 0.43
KCNH2 Q12809 1/20 0.43
KCNE1 P15382 1/20 0.37
CCR1 P32246 1/20 0.37
KCNQ1 P51787 1/20 0.37
SMN1; SMN2 Q16637 3/20 0.37
MEN1 O00255 2/20 0.37
KMT2A Q03164 2/20 0.37
HSD17B10 Q99714 1/20 0.37
ERCC1 P07992 1/20 0.37
FEN1 P39748 1/20 0.37
ERCC4 Q92889 1/20 0.37
CALCA P06881 2/20 0.36
LIPG Q9Y5X9 1/20 0.36
LMNA P02545 1/20 0.35
CYP3A4 P08684 1/20 0.34
CYP2C19 P33261 1/20 0.34
HTT P42858 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL368029 0.91 KCNH2 (0.43) CYP2C9KCNH2KCNE1CCR1KCNQ1
SCHEMBL368368 0.88 ERCC1 (0.39) CYP2C9KCNH2KCNE1CCR1KCNQ1
SCHEMBL368488 0.88 CYP2C9 (0.41) CYP2C9KCNH2KCNE1CCR1KCNQ1
SCHEMBL368702 0.87 CYP2C9 (0.39) CYP2C9KCNH2KCNE1CCR1KCNQ1
SCHEMBL368920 0.87 CYP2C9 (0.41) CYP2C9KCNH2KCNE1CCR1KCNQ1
SCHEMBL367198 0.86 KCNH2 (0.44) CYP2C9KCNH2KCNE1CCR1KCNQ1
SCHEMBL368726 0.85 PSMD14 (0.40) CYP2C9KCNH2KCNE1CCR1KCNQ1
SCHEMBL360076 0.85 CYP2C9 (0.43) CYP2C9KCNH2KCNE1CCR1KCNQ1
SCHEMBL367848 0.84 KCNH2 (0.45) CYP2C9KCNH2KCNE1CCR1KCNQ1
SCHEMBL367904 0.81 KCNH2 (0.37) CYP2C9KCNH2KCNE1CCR1KCNQ1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130178469-A1 NOVEL ANTIVIRAL AGENTS SHANGHAI INSTITUTE OF ORGANIC CHEMISTRY (SIOC) (CN) 2013-07-11 US disclosed
US-20130178469-A1 NOVEL ANTIVIRAL AGENTS SHANGHAI INSTITUTE OF ORGANIC CHEMISTRY (SIOC) (CN) 2013-07-11 US disclosed
US-20130178469-A1 NOVEL ANTIVIRAL AGENTS SHANGHAI INSTITUTE OF ORGANIC CHEMISTRY (SIOC) (CN) 2013-07-11 US disclosed
EP-2593460-A1 7, 9-NITROGEN RADICAL-4-OXO-4H-PYRIDO[L,2-A]PYRIMIDINE-2-CARBOXYLIC ACID BENZYLAMIDE ANTI-VIRALS Avexa Limited (AU) 2013-05-22 EP disclosed
WO-2012006680-A1 7, 9-NITROGEN RADICAL-4-OXO-4H-PYRIDO[L,2-A]PYRIMIDINE-2-CARBOXYLIC ACID BENZYLAMIDE ANTI-VIRALS AVEXA LIMITED (AU) 2012-01-19 WO disclosed
WO-2012006680-A1 7, 9-NITROGEN RADICAL-4-OXO-4H-PYRIDO[L,2-A]PYRIMIDINE-2-CARBOXYLIC ACID BENZYLAMIDE ANTI-VIRALS AVEXA LIMITED (AU) 2012-01-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130178469-A1 NOVEL ANTIVIRAL AGENTS EIF2AK2, IFNAR1, IRF3 CYP2C9 2213/4885KCNH2 4307/4885KCNE1 4338/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.